IGH/MAF Translocation, Dual Fusion Probe

FHPC-066

The translocation t(14;16) (q32.3;q23) involving c-MAF and IGH is present in 25% of myeloma cell lines and in 2-6% of primary Multiple Myeloma samples. A recent gene expression profiling of myeloma cell lines revealed that c-MAF transactivated cyclin D2 (a promoter of cell cycle progression), thus enhancing proliferation of myeloma cells. WWOX, a putative tumour suppressor gene, is a frequent target for loss of heterozygosity and chromosomal rearrangements in ovarian, breast, hepatocellular and prostate carcinomas as well as other neoplasias.

5 Tests, 10 Tests

Red/Green

Human

14q32.3/16q23

For Research Use Only. Not for use in diagnostic procedures.

Store at minus 20 centigrade

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.